Civica Rx has been nominated as a BioSpace Best Place to Work! Voting is open through this month and anyone can participate by voting on two biopharma industry categories, large company and small company (Civica is listed as a candidate in the small company section). Participants vote on their top three large and small companies from a predetermined list (with a few more questions for the #1 pick in each category). The survey takes about 5 minutes and no comments/essays are required. Civica was named a 2024 BioSpace Best Place to Work and we are proud to be nominated again! https://lnkd.in/gk457-Bt
Civica Rx’s Post
More Relevant Posts
-
Some interesting insights from the Q&A with Ken Song regarding RayzeBio's journey: 1. Quick Rise to Acquisition: RayzeBio swiftly progressed from Series A to acquisition within a remarkably short timeframe, showcasing effective strategic decision-making and capital deployment. 🚀 2. Navigating Funding Challenges: Despite facing a challenging fundraising environment, RayzeBio demonstrated resilience and strategic foresight by prioritizing proper capitalization over short-term concerns about dilution. 💡 Maintaining Discipline: Throughout the IPO process, RayzeBio remained disciplined, resisting the temptation to maximize gains and ensuring a successful debut on the stock market. 📉 3. Post-IPO Interest and Acquisition: Interestingly, RayzeBio garnered substantial acquisition interest only after going public, indicating that the IPO served as a catalyst for attracting strategic partners. 🔄 4. Future of Radiopharmaceuticals: Song envisions radiopharmaceuticals evolving into a major modality, with increased commitment from pharmaceutical companies and advancements in isotope availability driving further innovation. 🧪 RayzeBio's journey offers valuable insights into biotech entrepreneurship, strategic decision-making, and the evolving landscape of pharmaceutical innovation. 🌱
"What I have seen over the last 17-plus years is there are times when there’ll be almost irrational exuberance, but there will also be times when there’s irrational overconcern." Ken Song and I spoke about RayzeBio's 3-month sprint from Series A to B, taking a down round in 2022, going public when most others didn't and then inking a $4.1 billion M&A exit to Bristol Myers Squibb about 100 days later. #radiopharmaceuticals #biotech #pharma #acquisition #questionandanswer #qanda
-
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/gNCuQv4b #CDMO #viralvectors #genomicmedicine #genetherapy
-
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/eg7_Zqtk #CDMO #viralvectors #genomicmedicine #genetherapy
-
Providing Solutions & Technologies to Enterprises & Scientists for advancing the manufacturing of precision medicines
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/gPAk9D4z #CDMO #viralvectors #genomicmedicine #genetherapy
-
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/eg7_Zqtk #CDMO #viralvectors #genomicmedicine #genetherapy
-
Discovery Medical Sales Account Manager at Cytiva | Boston West & South | Platinum Sales Club-Rookie of the Year Award 2020
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/ePYbrKDf #CDMO #viralvectors #genomicmedicine #genetherapy
-
Discovery Medical Sales Account Manager at Cytiva | Boston West & South | Platinum Sales Club-Rookie of the Year Award 2020
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/ePYbrKDf #CDMO #viralvectors #genomicmedicine #genetherapy
-
MST Financial is proud to have supported Opthea Ltd (OPT.ASX) acting as Sole Lead Manager to the company’s A$227 million capital raising – the largest pre-Phase 3 readout biotech raise ever in Australia (ex CSL). The capital raising comprised of a A$10.0 million Institutional Placement and a $217.3 million accelerated non renounceable entitlement offer (ANREO). Proceeds of the offer will be used to continue advancing clinical development of OPT-302 for the treatment of wet AMD, including progressing the Phase 3 clinical program, CMC (chemistry, manufacturing, and controls) activities and Biologics License application (BLA) preparations. OPT-302 treats wet AMD, the leading cause of irreversible blindness, by improving vision in patients. #MSTFinancial #OptheaLtd #OPT #growthcapital #australianequities #ASX #finance #retinalspecialists #wetAMD #ophthalmology #macular #degeneration
-
-
Good Morning from New Jersey! It's Day One at the Nexus Conference - 21st BioPharma Clinical Trials! What a fantastic opportunity to connect with leaders and innovators in the world of clinical trials. Today, we are excited to participate in the Panel Discussion on Running Clinical Trials in Different Geographic Regions: Assessing Opportunities and Challenges, featuring Rui Rui Zhang Xiang Business Director. Stay tuned for insights and key takeaways on overcoming the complexities of global trials! #ClinicalTrials #Biopharma #PharmaInnovation
-
-
Discovery Medical Sales Account Manager at Cytiva | Boston West & South | Platinum Sales Club-Rookie of the Year Award 2020
Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/ePYbrKDf #CDMO #viralvectors #genomicmedicine #genetherapy
Congratulations on the nomination!